ProKidney, a forerunner in addressing chronic kidney disease (CKD) using advancements in cellular therapy, was established in 2015 following ten years of investigation. The primary product candidate of ProKidney, REACT® (Renal Autologous Cell Therapy), is a unique patented autologous cellular therapy that modifies the disease and has the potential to not just slow and stabilize CKD progression, but also potentially enhance kidney function in certain instances. REACT® has been granted the Regenerative Medicine Advanced Therapy (RMAT) designation, and has also received guidance from the FDA and EMA.